Clinical pharmacology principles for dosing, drug interactions, and patient s...
A skill for applying clinical pharmacology principles to research and practice. Covers pharmacokinetic/pharmacodynamic modeling, drug interaction assessment, therapeutic drug monitoring, and special population dosing.
The most widely used PK/PD model relates drug concentration to effect:
import numpy as np
import matplotlib.pyplot as plt
def emax_model(concentration: np.ndarray, emax: float, ec50: float,
hill: float = 1, baseline: float = 0) -> np.ndarray:
"""
Sigmoid Emax (Hill) model.
Args:
concentration: Drug concentration array
emax: Maximum effect
ec50: Concentration producing 50% of Emax
hill: Hill coefficient (steepness)
baseline: Baseline effect (E0)
"""
effect = baseline + (emax * concentration**hill) / (ec50**hill + concentration**hill)
return effect
# Example: dose-response curve
conc = np.logspace(-2, 3, 200)
effect = emax_model(conc, emax=100, ec50=10, hill=1.5)
fig, ax = plt.subplots(figsize=(8, 5))
ax.semilogx(conc, effect)
ax.set_xlabel('Concentration (ng/mL)')
ax.set_ylabel('Effect (%)')
ax.set_title('Sigmoid Emax Model')
ax.axhline(y=50, color='gray', linestyle='--', alpha=0.5)
ax.axvline(x=10, color='gray', linestyle='--', alpha=0.5)
ax.annotate('EC50', xy=(10, 50), fontsize=12)
plt.tight_layout()
def predict_cyp_interaction(victim_drug: dict, perpetrator_drug: dict) -> dict:
"""
Predict metabolic drug-drug interaction potential.
Args:
victim_drug: {'name': str, 'primary_cyp': str, 'fraction_metabolized': float}
perpetrator_drug: {'name': str, 'cyp_effects': dict}
cyp_effects maps CYP enzyme to 'inhibitor'|'inducer'|'none'
"""
cyp = victim_drug['primary_cyp']
fm = victim_drug['fraction_metabolized'] # fraction metabolized by this CYP
perp_effect = perpetrator_drug['cyp_effects'].get(cyp, 'none')
if perp_effect == 'inhibitor':
# AUC ratio = 1 / (1 - fm) for complete inhibition
auc_ratio = 1 / (1 - fm) if fm < 1 else float('inf')
risk = 'high' if auc_ratio > 5 else 'moderate' if auc_ratio > 2 else 'low'
elif perp_effect == 'inducer':
# Induction decreases exposure
auc_ratio = 1 - fm * 0.7 # approximate 70% induction
risk = 'high' if auc_ratio < 0.3 else 'moderate' if auc_ratio < 0.5 else 'low'
else:
auc_ratio = 1.0
risk = 'none'
return {
'victim': victim_drug['name'],
'perpetrator': perpetrator_drug['name'],
'affected_cyp': cyp,
'interaction_type': perp_effect,
'predicted_auc_ratio': round(auc_ratio, 2),
'clinical_risk': risk,
'recommendation': (
'Dose adjustment required' if risk == 'high'
else 'Monitor closely' if risk == 'moderate'
else 'No action needed'
)
}
Drugs requiring routine TDM due to narrow therapeutic windows:
| Drug | Therapeutic Range | Toxic Level | Monitoring Frequency |
|---|---|---|---|
| Vancomycin | AUC/MIC 400-600 | AUC/MIC > 600 | Trough before 4th dose |
| Lithium | 0.6-1.2 mEq/L | > 1.5 mEq/L | Weekly initially, then monthly |
| Digoxin | 0.8-2.0 ng/mL | > 2.0 ng/mL | At steady state (5-7 days) |
| Phenytoin | 10-20 mcg/mL | > 20 mcg/mL | 2 weeks after dose change |
| Tacrolimus | 5-15 ng/mL | > 20 ng/mL | Twice weekly post-transplant |
def bayesian_dose_adjustment(prior_cl: float, prior_cl_cv: float,
measured_conc: float, expected_conc: float,
current_dose: float) -> dict:
"""
Simple Bayesian dose adjustment using one-point TDM.
Args:
prior_cl: Population clearance estimate (L/hr)
prior_cl_cv: CV of clearance in population (0-1)
measured_conc: Observed trough concentration
expected_conc: Expected concentration at population CL
current_dose: Current dose (mg)
"""
# Individual clearance estimate (MAP approach, simplified)
ratio = expected_conc / measured_conc
individual_cl = prior_cl * ratio
# Bayesian shrinkage toward population
weight = 1 / (1 + prior_cl_cv**2)
posterior_cl = weight * prior_cl + (1 - weight) * individual_cl
# New dose to achieve target
target_conc = (measured_conc + expected_conc) / 2 # midpoint of range
new_dose = current_dose * (posterior_cl / prior_cl)
return {
'individual_CL': round(individual_cl, 2),
'posterior_CL': round(posterior_cl, 2),
'recommended_dose': round(new_dose, 1),
'dose_change_pct': round((new_dose - current_dose) / current_dose * 100, 1)
}
Dosing considerations for specific patient groups:
All clinical pharmacology studies should follow ICH guidelines (E4 for dose-response, E5 for ethnic factors, E7 for geriatric, E11 for pediatric). Report results in standardized population PK/PD formats compatible with FDA and EMA submission requirements.